Display Settings:


Send to:

Choose Destination
Urol Clin North Am. 2010 Feb;37(1):97-104, Table of Contents. doi: 10.1016/j.ucl.2009.11.012.

Neoadjuvant and adjuvant therapies in prostate cancer.

Author information

  • 1Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02215, USA.


Prostate cancer is the most common cancer in men in the United States and the second leading cause of cancer death. Advances in surgical therapies have paralleled advances in radiation therapy and chemotherapy for metastatic disease. There is a great interest in neoadjuvant and adjuvant therapies for patients at intermediate and high risk of recurrence and prostate cancer-specific death. Because high-risk prostate cancer patients can be readily identified by clinical criteria, many studies have attempted to use local and systemic adjuvant therapy to reduce the risk of recurrence. This review discusses neoadjuvant and adjuvant therapies in prostate cancer, including hormonal therapy, chemotherapy, and postoperative radiotherapy.

Copyright (c) 2010 Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk